HC Wainwright & Co. reiterates Buy rating on Telix Pharmaceuticals, $20 price target

HC Wainwright & Co. reiterated their Buy rating on Telix Pharmaceuticals's stock with a price target of $20.00.The price target implies an upside of 25.8% from the Sep 25 close of $15.90.Key takeaways from the analyst noteStrategic Acquisition of ITM: Telix's recent agreement to acquire ITM Isotope…